Effect of liraglutide 3.0 mg in individuals with obesity and moderate or severe obstructive sleep apnea: the SCALE Sleep Apnea randomized clinical trial
In the same trial, people on CagriSema lost an average of about 23% of their body weight over 68 weeks when measuring the effect assuming full adherence, or about 21% when accounting for all participants regardless of whether they completed treatment
Waltham, MA, USA) were used for chromatographic separation, and each sample of EV39 and EV42 was analyzed in duplicate for reliability
From a practical point of view, different GLP-1RAs offer different dosing and device experiences, allowing practitioners to tailor treatment according to the needs of the individual patient
If compounding is considered, we discuss sourcing, documentation, and risks so you can make an informed choice